The stock of Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) hit a new 52-week low and has $2.37 target or 14.00% below today’s $2.75 share price. The 9 months bearish chart indicates high risk for the $37.39 million company. The 1-year low was reported on Nov, 2 by Barchart.com. If the $2.37 price target is reached, the company will be worth $5.23M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 118,857 shares traded hands or 123.71% up from the average. Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) has declined 30.23% since March 31, 2016 and is downtrending. It has underperformed by 32.75% the S&P500.
Analysts await Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) to report earnings on November, 10.
According to Zacks Investment Research, “Imprimis Pharmaceuticals, Inc. is a pharmaceutical company focused on its proprietary ophthalmology and urology drug formulations. Imprimis recently launched its urology business, which includes a patented formulation to address patients suffering from interstitial cystitis.”
Insitutional Activity: The institutional sentiment increased to 1.2 in 2016 Q2. Its up 0.06, from 1.14 in 2016Q1. The ratio improved, as 3 funds sold all Imprimis Pharmaceuticals Inc shares owned while 2 reduced positions. 1 funds bought stakes while 5 increased positions. They now own 1.66 million shares or 37.14% less from 2.64 million shares in 2016Q1.
Geode Cap Mngmt Ltd Liability, a Massachusetts-based fund reported 17,570 shares. Blackrock Mngmt Ltd Liability Corp holds 0% or 1,966 shares in its portfolio. Manufacturers Life Ins The has 169 shares for 0% of their US portfolio. Berson & Corrado Advsrs Lc has 31,107 shares for 0.08% of their US portfolio. Marathon Mgmt has 25,000 shares for 0.05% of their US portfolio. Blackrock Fund Advsr last reported 32,979 shares in the company. Bank Of America De last reported 0% of its portfolio in the stock. Pnc Fin Svcs Group Inc holds 0% or 2,000 shares in its portfolio. Creative Planning accumulated 750 shares or 0% of the stock. Moreover, Northern Tru has 0% invested in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) for 43,667 shares. Opaleye Incorporated has 0.98% invested in the company for 265,000 shares. Vanguard Grp Inc Inc, a Pennsylvania-based fund reported 168,584 shares. Moreover, Marathon Asset Management L P has 0.17% invested in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) for 833,333 shares. Moreover, Bard Assoc has 0.13% invested in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) for 65,500 shares. Tower Research Cap Limited Liability Corp (Trc) last reported 548 shares in the company.
More notable recent Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) news were published by: Prnewswire.com which released: “Imprimis Pharmaceuticals Announces Availability of Lower-Cost Option for the …” on October 17, 2016, also Prnewswire.com with their article: “Imprimis Pharmaceuticals Strengthens Senior Leadership Team with Key Hires in …” published on August 15, 2016, Prnewswire.com published: “Imprimis Pharmaceuticals Registers its New Jersey Facility with the FDA as an …” on October 28, 2016. More interesting news about Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) were released by: Prnewswire.com and their article: “Imprimis Pharmaceuticals Announces Preliminary Revenue for Third Quarter 2015” published on October 20, 2015 as well as Prnewswire.com‘s news article titled: “Imprimis Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year …” with publication date: March 03, 2016.
IMMY Company Profile
Imprimis Pharmaceuticals, Inc. (Imprimis), incorporated on January 11, 2006, is engaged in the development, production and dispensing of compounded pharmaceuticals. The Firm operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Firm is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Firm also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas, including oncology, autoimmunity, chronic infectious diseases and endocrine and metabolic diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.